𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of combination 4′-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer

✍ Scribed by Charles Redman; Frank Lawton; Nicholas Stuart; Mary O'Brien; John Buxton; John Mould; Anula Chetiyawardana; Michael Crawford; Michael Patterson; Virginia Sykes; George Blackledge

Book ID
104688018
Publisher
Springer
Year
1989
Tongue
English
Weight
280 KB
Volume
23
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of combined 5-fluoroura
A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer
✍ Willy Mattsson; Finn Von Eyben; Lennart Hallsten; Göran Bjelkengren 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 2 views

In a Phase I1 study, 50 patients with advanced breast cancer were treated with a combination of 5fluorouracil(lOO0 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination c

A phase II and pharmacodynamic study of
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer
✍ Edwin M. Posadas; Meghan S. Liel; Virginia Kwitkowski; Lori Minasian; Andrew K. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

## Abstract ## BACKGROUND The primary objective of this study was to evaluate the biochemical effects of gefitinib on its target signal‐transduction pathways in patients with recurrent epithelial ovarian cancer (EOC). The secondary objectives included assessing clinical activity and toxicity and d

A phase 1 and pharmacodynamic study of d
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c